Product image of Mitomycine Substipharm (Mitomycin) supplied by GNH India

Mitomycine Substipharm

Active Ingredient:
Mitomycin
Origin:
EU

Mitomycine Substipharm (Mitomycin)

Mitomycin, the active ingredient in Mitomycine Substipharm, is an alkylating antineoplastic agent presented as a sterile injectable for intra‑arterial, intravenous, or intravesical use. It is employed in the treatment of several solid tumours, including bladder, gastric, pancreatic, breast and lung cancers, in adult oncology patients.

GNH India supplies Mitomycine Substipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from regulatory support and consistent product availability across multiple markets.

Manufacturer / TM Owner

Substipharm

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mitomycin is used in chemotherapy regimens targeting solid tumours that rely on DNA cross‑linking mechanisms.

  • Bladder cancer: reduces tumour recurrence after transurethral resection.
  • Gastric cancer: used in combination protocols for advanced disease.
  • Pancreatic cancer: incorporated into multi‑agent regimens for metastatic cases.
  • Breast cancer: applied in selected cases resistant to standard therapies.
  • Lung cancer: employed as part of combination chemotherapy for non‑small cell carcinoma.

How It Works

  • Mitomycin acts as a DNA cross‑linking agent. After intracellular reduction, it forms covalent bonds between adjacent guanine bases, creating interstrand cross‑links that block DNA replication and transcription. The resulting inhibition of DNA synthesis triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing cancer cells. The drug is most active in hypoxic tumor microenvironments where enzymatic activation is enhanced, and its cytotoxic effect is amplified when combined with radiation or other alkylating agents.

Side Effects

Mitomycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset commonly reported.
  • Myelosuppression: decreased white blood cells, platelets, and red cells.
  • Fatigue: generalized tiredness during treatment.
  • Mucositis: inflammation of the mouth and gastrointestinal lining.
  • Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects

  • Pulmonary toxicity: interstitial pneumonitis or fibrosis.
  • Hemorrhagic cystitis: bladder inflammation with bleeding.
  • Severe infection: due to profound neutropenia.
  • Renal impairment: reduced kidney function in susceptible patients.
  • Cardiotoxicity: rare cardiac dysfunction or arrhythmia.

Precautions & Warnings

When using Mitomycin, clinicians should observe several safety measures to minimize risk.

  • Baseline blood counts: obtain complete blood count before each cycle to monitor myelosuppression.
  • Renal function: assess serum creatinine and adjust dose in patients with impaired kidneys.
  • Pulmonary assessment: perform lung function tests if history of respiratory disease.
  • Concomitant nephrotoxic drugs: avoid or closely monitor agents that may worsen kidney injury.
  • Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and avoid breastfeeding.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mitomycin can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid)

  • Antimetabolites (e.g., methotrexate): combined use markedly increases myelosuppression.
  • High‑dose radiation therapy: synergistic toxicity to normal tissues.
  • Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Nephrotoxic agents (e.g., cisplatin, aminoglycosides): may exacerbate renal toxicity.
  • CYP450 inducers or inhibitors: can alter mitomycin activation pathways.
  • Anticoagulants (e.g., warfarin): increased bleeding risk due to mucosal damage.

Frequently Asked Questions

Mitomycine Substipharm contains mitomycin, an alkylating antineoplastic agent used in chemotherapy for several solid tumours, including bladder, gastric, pancreatic, breast and lung cancers. It is administered by intra‑arterial, intravenous or intravesical routes as part of a prescribed treatment regimen.

Mitomycin is a DNA cross‑linking agent. Inside cancer cells it is reduced to an active form that creates covalent bonds between adjacent guanine bases, forming interstrand cross‑links that block DNA replication and transcription, leading to cell‑cycle arrest and apoptosis.

The dosage of Mitomycine Substipharm is determined by the treating physician based on the specific cancer type, disease stage, patient weight, renal function and other clinical factors. Only a qualified prescriber may set the appropriate dose and schedule.

Mitomycin is classified as contraindicated in pregnancy because of its potential to cause fetal harm. Women of child‑bearing potential should use effective contraception. Breastfeeding is not recommended, as the drug may be excreted in milk and affect the infant.

To place an enquiry, visit the product page on gnhindia.com and submit the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mitomycin belongs to the alkylating class and works by DNA cross‑linking, which differs from antimetabolites that inhibit nucleotide synthesis or taxanes that disrupt microtubules. Its activity is especially pronounced in hypoxic tumour environments, and it is often combined with other agents to enhance overall response.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and follow aseptic techniques during preparation and administration.

Mitomycine Substipharm is supplied as a sterile injectable solution. It is given by a qualified healthcare professional via intra‑arterial, intravenous or intravesical infusion, according to the prescriber’s instructions and the specific treatment protocol.

Serious adverse events include pulmonary toxicity (interstitial pneumonitis or fibrosis), hemorrhagic cystitis, severe myelosuppression leading to infection, renal impairment and rare cardiotoxicity. Patients should be monitored closely for respiratory symptoms, blood counts and kidney function throughout therapy.

Mitomycine Substipharm is contraindicated in patients with known hypersensitivity to mitomycin, pregnant or breastfeeding women, and individuals with severe renal or hepatic impairment where dose adjustment is not feasible. Caution is also advised for patients with pre‑existing lung disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mitomycin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT